Dr. Janjigian Discusses MSI Testing in Gastric Cancer

Yelena Y. Janjigian, MD
Published: Tuesday, Sep 19, 2017



Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.

Though MSI-high is a relatively rare subset of gastric cancer, it is very important to distinguish these patients, says Janjigian.

MSI status must be routinely tested, Janjigian adds, because even if patients do not meet MSI criteria, a higher mutational burden may increase their chances of responding to therapy.
 
SELECTED
LANGUAGE


Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.

Though MSI-high is a relatively rare subset of gastric cancer, it is very important to distinguish these patients, says Janjigian.

MSI status must be routinely tested, Janjigian adds, because even if patients do not meet MSI criteria, a higher mutational burden may increase their chances of responding to therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x